The Latest Cardiac and Vascular News
Initial 20 Patients Enrolled in the First-in-Human Trial Had a 0% Rate of Reintervention. LOS ALTOS, Calif., April 23, 2025 /PRNewswire/ — The initial long-term results from EFEMORAL I were presented today by Principal Investigator Prof. Andrew Holden (Auckland City Hospital, Auckland, New Zealand) at the Charing Cross Symposium in London, UK. EFEMORAL I is a […]
Grant Proceeds Will Support Pre-Clinical Studies LOS ALTOS, Calif., Sept. 22, 2022 /PRNewswire/ — Efemoral Medical, developer of advanced interventional bioresorbable therapies, announced today that it has been awarded a Phase II Small Business Innovation Research (SBIR) grant by the National Institutes of Health. SBIR grants are intended to stimulate technological innovation and […]
New bioresorbable treatment option aims to improve outcomes for patients suffering from peripheral arterial disease LOS ALTOS, Calif., Dec. 14, 2020 /PRNewswire/ — Efemoral Medical, developer of advanced interventional bioresorbable therapies, today announced the first-in-human (FIH) use of the company’s Efemoral™ Vascular Scaffold System (EVSS) with FlexStep™ Technology in the EFEMORAL I FIH clinical study. […]
